Selective Gamma Globulin Treatment in Kawasaki Disease: The Comparison between Single 1g/kg and 2g/kg.
- Author:
Su Mi IHN
1
;
Ren Zhe ANN
;
Hong Ryang KIL
;
Young Hun CHUNG
Author Information
1. Department of Pediatrics, College of Medicine, Chungnam National University, Taejon, Korea.
- Publication Type:Original Article
- Keywords:
Kawasaki disease;
Intravenous gamma globulin
- MeSH:
Aspirin;
Child;
Chungcheongnam-do;
Coronary Vessels;
gamma-Globulins*;
Humans;
Mucocutaneous Lymph Node Syndrome*;
Prospective Studies
- From:Journal of the Korean Pediatric Society
2000;43(7):920-925
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Treatment of Kawasaki disease with intravenous gamma globulin(IVGG), together with aspirin, has been dernonstrated to be safe and effective in preventing coronary artery lesion and systemic inflarnmation, but optimal IVGG dosage and administration method are still controversial. We compared the therapeutic efficacy and clinical response of single IVGG 1g/kg to that of IVGG lg/kg for comparable risk group of Kawasaki disease. METHODS: We conducted a prospective study involving 63 children with Kawasaki disease requiring IVGG treatment(Harada score> or =4) at Chungnam National University Hospital from February 1996 to January 1999. The children were assigned to receive IVGG either as a single infusion of 1g/kg(A group, 32 person) or 2g/kg(B group, 31 person) and aspirn(100mg/kg/day through acute phase, then 3 to 5mg/kg/day for 8 weeks of duration). RESULTS: There were no significant difference between the two groups according to clinical and laboratry data, including coronary artery lesions(group A, 31.3% and group B, 29.0%) before treatment. After IVGG treatment ratio of complication with coronary artery lesion(group A 1/32=3.1% and group B, 2/31=6.5%) and that of retreatment(group A, 4/32=12.5%, group B, 2/31=6.5%), duration of fever(group A, 1.3+/-1.6 days and group B, 0.7+/-1.4 days), hospital stay(group A, 7.0+/-1.4 days and group B, 6.5+/-2.0 days), laboratory finding and side effects of IVGG were not significantly different(P>0.05). The total dosage of IVGG was significantly lower in group A than group B(group A, 1.16+/-0.37g/kg, 375,421+/-207,351won and group B, 2.10+/-0.40g/kg, 641,498+/-274,750won (P<0.05). CONCLUSION: The therapeutic efficacy and clinical response of single 1g/kg therapy are comparable to that of single 2g/kg therapy.
